Abstract
Quinolone antibacterial drugs inhibit DNA gyrase, a type 2 topoisomerase. Since topoisomerases are present in eukaryotic cells, it was of interest to evaluate the antifungal activities of two clinically available quinolones, ciprofloxacin and trovafloxacin, alone and in combination with amphotericin B or fluconazole, in vitro against Candida albicans and in a murine model of invasive candidiasis. The in vitro activity of trovafloxacin was also tested against other yeasts and molds. In vitro, trovafloxacin exhibited no antifungal activity against any of the fungi (MIC, >250 microg/ml). There was also no effect of the quinolone on the in vitro activity of either antifungal drug. Marked antifungal effects were seen, however, in the murine model of candidiasis. In all experiments, control mice infected intravenously with C. albicans were dead by day 24. While either quinolone had minimal effects on survival of mice when used alone in oral doses of up to 40 mg/kg twice daily, the combination of the quinolone with fluconazole (40 or 80 mg/kg given twice daily by oral gavage) was more effective in prolonging survival than was fluconazole alone. Colony counts of kidneys on days 12 and 30 showed similar reductions in C. albicans recovered from mice treated with fluconazole with or without trovafloxacin or amphotericin B with or without trovafloxacin. Survival of mice treated with a suboptimal dose of amphotericin B (0.2 mg/kg/day) was also improved when trovafloxacin (40 mg/kg) given twice daily was included (0 versus 27%, respectively; P < 0.05). While the mechanisms of action of the combination of trovafloxacin and amphotericin B or fluconazole are unclear, further work focused on fungal topoisomerase inhibition and the mechanism of the antifungal effect of quinolone antibacterial drugs is warranted.
Full Text
The Full Text of this article is available as a PDF (170.0 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Dykstra C. C., McClernon D. R., Elwell L. P., Tidwell R. R. Selective inhibition of topoisomerases from Pneumocystis carinii compared with that of topoisomerases from mammalian cells. Antimicrob Agents Chemother. 1994 Sep;38(9):1890–1898. doi: 10.1128/aac.38.9.1890. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fostel J., Montgomery D., Lartey P. Comparison of responses of DNA topoisomerase I from Candida albicans and human cells to four new agents which stimulate topoisomerase-dependent DNA nicking. FEMS Microbiol Lett. 1996 May 1;138(2-3):105–111. doi: 10.1111/j.1574-6968.1996.tb08142.x. [DOI] [PubMed] [Google Scholar]
- Fu K. P., Hetzel N., Gregory F. J., Hung P. P. Therapeutic efficacy of cefpiramide-ciprofloxacin combination in experimental Pseudomonas infections in neutropenic mice. J Antimicrob Chemother. 1987 Oct;20(4):541–546. doi: 10.1093/jac/20.4.541. [DOI] [PubMed] [Google Scholar]
- Gellert M., Mizuuchi K., O'Dea M. H., Itoh T., Tomizawa J. I. Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proc Natl Acad Sci U S A. 1977 Nov;74(11):4772–4776. doi: 10.1073/pnas.74.11.4772. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Marklein G. Quinolones in everyday clinical practice: respiratory tract infections and nosocomial pneumonia. Chemotherapy. 1996 Mar;42 (Suppl 1):33–42. doi: 10.1159/000239490. [DOI] [PubMed] [Google Scholar]
- Nakajima R., Kitamura A., Someya K., Tanaka M., Sato K. In vitro and in vivo antifungal activities of DU-6859a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungi. Antimicrob Agents Chemother. 1995 Jul;39(7):1517–1521. doi: 10.1128/aac.39.7.1517. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Shen L. L., Fostel J. M. DNA topoisomerase inhibitors as antifungal agents. Adv Pharmacol. 1994;29B:227–244. doi: 10.1016/s1054-3589(08)61140-0. [DOI] [PubMed] [Google Scholar]
- Sugar A. M., Hitchcock C. A., Troke P. F., Picard M. Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob Agents Chemother. 1995 Mar;39(3):598–601. doi: 10.1128/AAC.39.3.598. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sugar A. M., Liu X. Comparison of three methods of antifungal susceptibility testing with the proposed NCCLS standard broth macrodilution assay: lack of effect of phenol red. National Committee for Clinical Laboratory Standards. Diagn Microbiol Infect Dis. 1995 Mar;21(3):129–133. doi: 10.1016/0732-8893(95)00067-k. [DOI] [PubMed] [Google Scholar]
- Sugar A. M., Salibian M., Goldani L. Z. Saperconazole therapy of murine disseminated candidiasis: efficacy and interactions with amphotericin B. Antimicrob Agents Chemother. 1994 Feb;38(2):371–373. doi: 10.1128/aac.38.2.371. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sugino A., Peebles C. L., Kreuzer K. N., Cozzarelli N. R. Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc Natl Acad Sci U S A. 1977 Nov;74(11):4767–4771. doi: 10.1073/pnas.74.11.4767. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Thadepalli H., Reddy U., Chuah S. K., Thadepalli F., Malilay C., Polzer R. J., Hanna N., Esfandiari A., Brown P., Gollapudi S. In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli. Antimicrob Agents Chemother. 1997 Mar;41(3):583–586. doi: 10.1128/aac.41.3.583. [DOI] [PMC free article] [PubMed] [Google Scholar]